Skip to main
HIMS
HIMS logo

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 29%
Buy 6%
Hold 47%
Sell 12%
Strong Sell 6%

Bulls say

Hims & Hers Health Inc. demonstrated impressive growth in its most recent quarter, with total revenue increasing by 95.1% year-over-year, largely driven by a 98.3% increase in online revenue to $470.8 million. The company expanded its subscriber base significantly, adding 182,000 new subscribers to reach 2.2 million, reflecting a 45% year-over-year growth and showcasing strong demand for its telehealth services. Additionally, management anticipates that the weight loss segment will contribute approximately 30% of revenue in fiscal year 2025, a substantial increase from 15% in fiscal year 2024, indicating a robust strategy for future growth and enhanced profitability.

Bears say

Hims & Hers Health faces significant challenges due to increasing competition from venture-backed companies that can leverage their financial resources to undercut prices, which may lead to a loss of market share and compressed profit margins. Furthermore, the company's operating margins have already experienced a decline, reported at 8.9% compared to an expected 10.6%, primarily driven by lower pricing and increased costs related to marketing and product mix. Lastly, with shares trading at over 4x EV/Sales and maintaining high valuations amidst these margin pressures, the overall financial outlook appears precarious.

HIMS has been analyzed by 17 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 6% recommend Buy, 47% suggest Holding, 12% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 17 analysts, HIMS has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.